Taysha Gene Therapies (TSHA) Interest Coverage Ratio (QoQ) (2021 - 2026)
Taysha Gene Therapies (TSHA) Interest Coverage Ratio (QoQ) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Taysha Gene Therapies | 2.14 Bn | 2.14 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 99.97% |
| Dec 31, 2025 | -215,694.71% |
| Sep 30, 2025 | -7.32% |
| Jun 30, 2025 | 59.60% |
| Mar 31, 2025 | -149.04% |
| Dec 31, 2024 | 677.21% |
| Sep 30, 2024 | 59.88% |
| Jun 30, 2024 | -30.36% |
| Mar 31, 2024 | 86.51% |
| Dec 31, 2023 | -746.33% |
| Sep 30, 2023 | -105.04% |
| Jun 30, 2023 | 48.93% |
| Mar 31, 2023 | 94.62% |
| Dec 31, 2022 | -12.02% |
| Sep 30, 2022 | 47.42% |
| Jun 30, 2022 | 11.71% |
| Mar 31, 2022 | -2,510.20% |
| Dec 31, 2021 | 97.91% |
| Sep 30, 2021 | -930.14% |
| Jun 30, 2021 | 93.99% |